natgillin/translations-raw huggingface dataset:
An inverse relationship between apparent clearance and dose was noted in healthy subjects. 
Pri zdravih preskušancih so opazili obratno sorazmerje med navideznim očistkom in odmerkom.
Cytotoxic actions of epoetin alfa on bone marrow cells could not be detected. 
Citotoksičnega delovanja epoetina alfa na celice kostnega mozga ni bilo mogoče zaznati.
Your pre-filled syringe has a passive needle guard device attached to it in order to protect you from needle stick injury. 
Vaša napolnjena injekcijska igla je opremljena s pasivnim spripomočkom za zaščito igle, ki služi za zaščito pred vbodom z iglo.
Solution for injection in pre-filled syringe (injection). 
Raztopina za injiciranje v napolnjeni injekcijski brizgi (injekcija).
Epoetin alfa was administered subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery. 
Epoetin alfa so injicirali subkutano enkrat na dan 10 dni pred kirurškim posegom, na dan kirurškega posega in 4 dni po kirurškem posegu.
The effect of epoetin alfa (300 IU/kg or 100 IU/kg) on the exposure to allogeneic blood transfusion has been evaluated in a placebo-controlled, double-blind clinical trial in non-iron deficient adult patients scheduled for major elective orthopaedic hip or knee surgery. 
Učinek epoetina alfa (300 i.e./kg ali 100 i.e./kg) na izpostavljenost alogenski transfuziji krvi so ocenili v s placebo nadzorovanem, dvojno slepem kliničnem preskušanju pri odraslih bolnikih brez pomanjkanja železa, ki so imeli načrtovan večji kirurški poseg na kolku ali kolenu.
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 mL of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation (see Posology, Adult haemodialysis patients). 
Injiciranje se lahko opravi tudi ob koncu dialize skozi fistulne igle, ki mu sledi injiciranje 10 ml izotonične fiziološke raztopine, da se cevke splaknejo in da se zagotovi zadovoljiv vnos zdravila v obtok (glejte Odmerjanje, Odrasli bolniki na hemodializi).
• When the plunger is pushed as far as it will go, take out the needle and let go of the skin. 
• Ko ste bat potisnili do konca, izvlecite iglo in izpustite kožo.
Your syringe has a needle-trap attached to it which is designed to specifically help prevent accidental needle stick injuries following the proper administration of injectable medicines. 
Na vašo brizgo je nameščen varovalni nastavek Needle-Trap, ki je namenjen preprečevanju neželenih vbodov z iglo po pravilni uporabi zdravil za injiciranje.
In chronic renal failure patients the rate of increase in haemoglobin should be approximately 1 g/dL (0.62 mmol/L) per month and should not exceed 2 g/dL (1.25 mmol/L) per month to minimise risks of an increase in hypertension. 
Pri bolnikih s kronično ledvično okvaro mora biti hitrost zvečevanja koncentracije hemoglobina približno 1 g/dl (0,62 mmol/l) na mesec in ne sme presegati 2 g/dl (1,25 mmol/l) na mesec za zmanjšanje tveganja za poslabšanje hipertenzije.
The recommended starting dose is Retacrit 450 IU/kg (maximum total dose is 40 000 IU) administered subcutaneously once every week, with not less than 5 days between doses. 
Priporočeni začetni odmerek je 450 i.e./kg zdravila Retacrit (največji skupni odmerek je 40.000 i.e.), ki ga dajemo subkutano enkrat tedensko z vsaj 5-dnevnimi presledki med odmerki.
•Retacrit is used in moderatelyanaemic adults who donate some of their blood before surgery, so that it can be given back to them during or after the operation. 
- Zdravilo Retacrit se uporablja za zmerno slabokrvne odrasle, ki bodo pred operacijo darovali nekaj svoje krvi, tako da jim jo bodo med operacijo lahko vrnili.
In the double-blind study, patients were treated with epoetin alfa 600 IU/kg or placebo intravenously once daily every 3 to 4 days over 3 weeks (total 6 doses). 
V dvojno slepi študiji so bolnike zdravili z epoetinom alfa 600 i.e./kg ali placebom intravensko enkrat na dan vsake 3 do 4 dni v obdobju 3 tednov (skupaj 6 odmerkov).
It is recommended that initial erythroid response be assessed 8 to 12 weeks following initiation of treatment. 
8 do 12 tednov po začetku zdravljenja.
Patients with very low initial haemoglobin (<6 g/dL or <3.75 mmol/L) may require higher maintenance doses than patients whose initial anaemia is less severe (>8 g/dL or >5 mmol/L). 
Bolniki z zelo nizkim začetnim nivojem hemoglobina (< 6 g/dl ali < 3,75 mmol/l) lahko potrebujejo višje vzdrževalne odmerke kot bolniki z manj hudo začetno anemijo (> 8 g/dl ali > 5 mmol/l).
Only take one dose of Retacrit from each syringe. 
Iz vsake injekcijske brizge vzemite samo 1 odmerek zdravila Retacrit.
You can press an antiseptic swab over the injection site for a few seconds after the injection. 
Po injiciranju lahko na mesto injiciranja za nekaj sekund pritisnete z antiseptično blazinico.
• an observed 9% increase in risk for PD or death in the epoetin zeta plus SOC group from a primary analysis and a 15% increased risk that cannot be statistically ruled out in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 10 to 12 g/dL (6.2 to 7.5 mmol/L). 
• z 9-odstotnim povečanjem tveganja za napredovanje bolezni ali smrt v skupini, ki je prejemala epoetin zeta in standardno oskrbo, ugotovljenim v primarni analizi, in 15-odstotnim povečanjem tveganja, ki ga statistično ni mogoče izključiti, pri bolnikih z metastatskim rakom dojk, ki so prejemali kemoterapijo in pri katerih so z dajanjem želeli doseči koncentracijo hemoglobina v razponu od 10 do 12 g/dl (od 6,2 do 7,5 mmol/l).
Adult peritoneal dialysis patients 
Odrasli bolniki na peritonealni dializi
Paediatric patients with very low initial haemoglobin (<6.8 g/dL or <4.25 mmol/L) may require higher maintenance doses than patients whose initial haemoglobin is higher (>6.8 g/dL or >4.25 mmol/L). 
Pediatrični bolniki z zelo nizkim začetnim nivojem hemoglobina (< 6,8 g/dl ali < 4,25 mmol/l) lahko potrebujejo višje vzdrževalne odmerke kot bolniki z višjim začetnim nivojem hemoglobina (> 6,8 g/dl ali > 4,25 mmol/l).
*Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell line. 
* pridobljeno iz celične linije jajčnika kitajskega hrčka (CHO -"Chinese Hamster Ovary") s tehnologijo rekombinantne DNA
Retacrit should not be used and discarded 
Zdravila Retacrit se ne sme uporabljati in ga morate zavreči,
• Before use, leave the Retacrit syringe to stand until it reaches room temperature. 
• Pred uporabo injekcijsko brizgo z zdravilom Retacrit pustite, da stoji toliko časa, da se pred uporabo ogreje na sobno temperaturo.
Very common: may affect more than 1 in 10 people. 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov.
The incidence of bone marrow fibrosis was not increased in a study of haemodialysis patients who were treated with epoetin alfa for 3 years compared to a matched control group of dialysis patients who had not been treated with epoetin alfa. 
V študiji bolnikov na hemodializi se pogostnost fibroze kostnega mozga pri bolnikih, ki so jih tri leta zdravili z epoetinom alfa, ni povečala v primerjavi z ustrezno kontrolno skupino, ki je niso zdravili z epoetinom alfa).
In a double-blind, placebo-controlled, multicentre, quality of life study in CRF patients on haemodialysis, clinically and statistically significant improvement was shown in the patients treated with epoetin alfa compared to the placebo group when measuring fatigue, physical symptoms, relationships and depression (Kidney Disease Questionnaire) after six months of therapy. 
V dvojno slepi, s placebom nadzorovani multicentrični študiji kakovosti življenja pri bolnikih s kronično ledvično odpovedjo na hemodializi so pri bolnikih, ki so se zdravili z epoetinom alfa, z merjenjem utrujenosti, telesnih simptomov, razmerij in depresije (vprašalnik o ledvični bolezni) po 6 mesecih zdravljenja dokazali klinično in statistično pomembno izboljšanje v primerjavi s skupino, ki je prejemala placebo.
Retacrit is indicated in adults in a predonation programme to increase the yield of autologous blood. 
Zdravilo Retacrit je indiciranopri odraslih v programu avtologne transfuzije za povečanje količine avtologne krvi.
Rare: may affect up to 1 in 1 000 people. 
Redki: pojavijo se lahko pri največ 1 od 1.000 bolnikov.
Patients should be monitored closely to ensure that the lowest approved dose of Retacrit is used to provide adequate control of anaemia and of the symptoms of anaemia. 
Bolnike morate skrbno nadzorovati, da bi zagotovili uporabo najnižjega odobrenega odmerka zdravila Retacrit za primeren nadzor anemije in simptomov anemije.
From pretreatment to presurgery, the mean increase in haemoglobin in the 600 IU/kg weekly group (1.44 g/dL) was twice than that observed in the 300 IU/kg daily group (0.73 g/dL). 
Od obdobja pred zdravljenjem do časa pred kirurškim posegom je bilo povprečno povečanje koncentracije hemoglobina v skupini s 600 i.e./kg na teden (1,44 g/dl) dvakrat večje od tistega, ki so ga opazili v skupini s 300 i.e./kg na dan (0,73 g/dl).
In patients scheduled for major elective orthopaedic surgery with a pretreatment haemoglobin of >10 to ≤ 13 g/dL, epoetin alfa has been shown to decrease the risk of receiving allogeneic transfusions and hasten erythroid recovery (increased haemoglobin levels, haematocrit levels, and reticulocyte counts). 
Dokazali so, da epoetin alfa pri bolnikih, naročenih na večji elektivni ortopedski kirurški poseg s koncentracijo hemoglobina pred zdravljenjem > 10 do ≤ 13 g/dl, zmanjša tveganje za prejem alogenske transfuzije in pospeši eritroidno okrevanje (povečanje koncentracije hemoglobina, vrednosti hematokrita in števila retikulocitov).
Patients with CRF not on dialysis demonstrated a dose-dependent and sustained increase in haematocrit when epoetin alfa was administered by either an intravenous or subcutaneous route. 
Pri bolnikih s kronično ledvično odpovedjo, ki se še ne zdravijo z dializo, se je pokazalo od odmerka odvisno in trajno povečanje vrednosti hematokrita, ko so epoetin alfa dajali bodisi intravensko bodisi subkutano.
Epoetin alfa has been studied in clinical trials in adult anaemic CRF patients, including haemodialysis and pre-dialysis patients, to treat anaemia and maintain haematocrit within a target concentration range of 30 to 36%. 
Epoetin alfa so preučevali v kliničnih preskušanjih pri odraslih anemičnih bolnikih s kronično ledvično odpovedjo, vključno z bolniki, ki se zdravijo s hemodializo, in s tistimi, ki se z dializo še ne zdravijo, za zdravljenje anemije in ohranjanje vrednosti hematokrita znotraj ciljnega razpona koncentracij od 30 do 36 %.
For patients scheduled for major elective orthopaedic surgery, iron supplementation (elemental iron 200 mg/day orally) should be administered throughout the course of epoetin zeta therapy. 
Bolnikom, ki so naročeni na večji elektivni ortopedski kirurški poseg, je treba dodajati železo (elementarno železo 200 mg/dan peroralno) tekom celotnega cikla zdravljenja z epoetinom zeta.
A tendency towards increased risk estimates for all-cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see sections 4.2 and 4.4). 
V povezavi z z večjimi kumulativni odmerki ESA so opazili nagnjenost k povečanemu tveganju za umrljivost zaradi vseh vzrokov ter za kardiovaskularne in cerebrovaskularne dogodke ne glede na sladkorno bolezen ali dializni status (glejte poglavji 4.2 in 4.4).
There are no or limited amount of data from the use of epoetin zeta in pregnant women. 
Podatkov o uporabi epoetina zeta pri nosečnicah ni oziroma so omejeni.
• shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 12 to 14 g/dL (7.5 to 8.7 mmol/L), 
• s skrajšanim časom celokupnega preživetja in povečanjem števila smrti, ki jih pripisujejo napredovanju bolezni po 4 mesecih pri bolnikih z metastaznim rakom dojk, ki so prejemali kemoterapijo in pri katerih so z dajanjem želeli doseči koncentracijo hemoglobina v razponu od 12 do 14 g/dl (od 7,5 do 8,7 mmol/l);
In the single-blind study, patients were treated with epoetin alfa 300 IU/kg or 600 IU/kg or placebo intravenously once daily every 3 to 4 days over 3 weeks (total 6 doses). 
V enojno slepi študiji so bolnike zdravili z epoetinom alfa 300 i.e./kg ali 600 i.e./kg ali placebom intravensko enkrat na dan vsake 3 do 4 dni v obdobju 3 tednov (skupaj 6 odmerkov).
The half-life of erythropoietin following multiple dose intravenous administration is approximately 4 hours in healthy subjects. 
Razpolovni čas eritropoetinapo intravenskem dajanju večkratnih odmerkov je pri zdravih preskušancih približno 4 ure.
A randomised, open-label, multicentre study was conducted in 2 098 anaemic women with metastatic breast cancer, who received first line or second line chemotherapy. 
Pri 2.098 anemičnih ženskah z metastatskim rakom dojk, ki so prejemale prvo ali drugi linijo kemoterapije, so opravili randomizirano, odprto multicentrično študijo.
• Take the cover off the syringe by holding the barrel and pulling the cover off carefully without twisting it. Don't push the plunger, touch the needle or shake the syringe. 
• Pokrovček snemite z brizge tako, da jo držite za trup in pokrovček previdno potegnete z brizge ne da bi ga zvijali.
There was no accumulation after multiple dose administration of 600 IU/kg administered subcutaneously weekly. 
Do akumulacije po dajanju večkratnih odmerkov 600 i.e./kg subkutano enkrat tedensko ni prihajalo.
Common in dialysis Includes arterial and venous, fatal and non fatal events, such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, arterial thrombosis (including myocardial infarction), cerebrovascular accidents (including cerebral infarction and cerebral haemorrhage) transient ischaemic attacks, and shunt thrombosis (including dialysis equipment) and thrombosis within arteriovenous shunt aneurisms Addressed in the subsection below and/or in section 4.4 
Vključuje arterijske in venske dogodke, s smrtnim izidom in brez njega, kot so globoka venska tromboza, pljučna embolija, tromboza mrežnice, arterijska tromboza (vključno z miokardnim infarktom), cerebrovaskularne dogodke (vključno s cerebralnim infarktom in cerebralno krvavitvijo), prehodne ishemične napade in trombozo šanta (vključno z dializno opremo) in trombozo v arteriovenskih anevrizmah šanta.
Pharmacokinetic data in neonates is limited. 
Farmakokinetični podatki pri novorojenčkih so omejeni.
Significantly fewer patients received RBC transfusions in the epoetin alfa plus SOC arm (5.8% versus 11.4%); however, significantly more patients had thrombotic vascular events in the epoetin alfa plus SOC arm (2.8% versus 1.4%). 
V skupini, ki je prejemala epoetin alfa in standardno oskrbo, je pomembno manj bolnic prejelo transfuzije (5,8 % v primerjavi z 11,4 %), vendar pa je v skupini, ki je prejemala epoetin alfa in standardno oskrbo, pomembno več bolnic doživelo trombotične žilne dogodke (2,8 % v primerjavi z 1,4 %).
Do not try to replace the needle cover. 
Ne poskušajte ponovno namestiti pokrovčka.
The other ingredients are disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, calcium chloride dihydrate, polysorbate 20, glycine, leucine, isoleucine, threonine, glutamic acid, phenylalanine, water for injections, sodium hydroxide (pH adjuster), hydrochloric acid (pH adjuster). 
Druge sestavine zdravila so dinatrijev fosfat dihidrat, natrijev dihidrogenfosfat dihidrat, natrijev klorid, kalcijev klorid dihidrat, polisorbat 20, glicin, levcin, izolevcin, treonin, glutamatna kislina, fenilalanin, voda za injekcije, natrijev hidroksid (za prilagoditev pH), klorovodikova kislina (za prilagoditev pH).
This includes any possible side effects not listed in this leaflet. 
Posvetujte se tudi, če opazite katere koli neželene učinke ki niso navedeni v tem navodilu.
Screening sEPO <200 mU/ml (N) 
Skupaj (n) sEPO ob presejanju < 200 mU/ml (n) Hemoglobin (g/l)
No other ESA therapy should be commenced because of the risk of cross-reaction. 
Zaradi tveganja navzkrižne reakcije ne smemo uvesti nobenega drugega zdravljenja z ESA.
• Dispose of your used syringe in a sharps container. 
• Uporabljeno injekcijsko brizgo odložite v zbiralnik za ostre predmete.
• Place the plastic catcher of the needle-trap against a hard, stable surface and with one hand pivot the syringe barrel upward against the needle forcing the needle into the catcher where it locks in place (an audible 'click” is heard when the needle is locked in the catcher). 
Potem brizgo z eno roko upognite navzgor; s tem potisnite iglo v plastično varovalo, da se v njem zaskoči (ko se igla zaskoči, je slišen "klik").
tiredness and dizziness. 
bistra, brezbarvna raztopina
Anaemia symptoms and sequelae may vary with age, gender and co-morbid medical conditions; a physician's evaluation of the individual patient's clinical course and condition is necessary. 
Simptomi anemije in z njo povezane posledice se lahko spreminjajo glede na starost, spol in sočasna bolezenska stanja; zdravnik mora oceniti klinični potek in stanje vsakega posameznega bolnika.
• decreased locoregional control in patients with advanced head and neck cancer receiving radiation therapy when administered to achieve a haemoglobin concentration level of greater than 14 g/dL (8.7 mmol/L), 
• z zmanjšanim lokoregionalnim nadzorom pri bolnikih z napredovalim rakom glave in vratu, ki so prejemali obsevalno zdravljenje in pri katerih so z dajanjem želeli doseči koncentracijo hemoglobina, večjo od 14 g/dl (8,7 mmol/l);
The AUCs of the respective pharmacodynamic parameters were similar between the 150 IU/kg, 3 times-per-week and 40 000 IU, once-weekly dosing regimens in healthy subjects and also in anaemic cancer subjects. 
Vrednosti AUC zadevnih farmakodinamičnih parametrov so bile podobne pri režimu odmerjanja 150 i.e./kg trikrat na teden in pri režimu odmerjanja 40.000 i.e. enkrat na teden, tako pri zdravih preskušancih kot pri anemičnih preskušancih z rakom.
If you have any further questions on the use of this product, ask your doctor, nurse or pharmacist. 
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
The safety of epoetin zeta has not been established in patients with hepatic dysfunction. 
Varnost epoetina zeta pri bolnikih z motnjo delovanja jeter ni bila dokazana.
Epoetin alfa was evaluated in an open-label, non-randomised, open dose-range, 52-week clinical study in paediatric CRF patients undergoing haemodialysis. 
Epoetin alfa so ocenili v odprti, nerandomizirani 52-tedenski študiji, z odprtim razponom odmerka pri pediatričnih bolnikih s kronično ledvično odpovedjo, ki so se zdravili s hemodializo.
• Retacrit is used to treat anaemia in adults with a bone marrow disorder that causes a severe disruption in the creation of blood cells (myelodysplastic syndromes). 
- Zdravilo Retacrit se uporablja za zdravljenje anemije pri slabokrvnih odraslih z boleznijo kostnega mozga, ki močno ovira tvorbo krvnih celic (mielodisplastičnimi sindromi).
Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients). 
Združeno post hoc analiza kliničnih študij z ESA so opravili pri bolnikih s kronično ledvično odpovedjo (pri bolnikih, ki so na dializi ali niso na dializi, ki imajo sladkorno bolezen ali je nimajo).
Cancer patients being treated with epoetin zeta should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter. 
Pri bolnikih z rakom, ki se zdravijo z epoetinom zeta, je treba redno meriti koncentracije hemoglobina, dokler se raven ne ustali, zatem pa v rednih časovnih intervalih.
Stop using Retacrit if you develop these symptoms and contact your doctor or seek medical attention immediately. 
Če se pri vas pojavijo ti simptomi, prenehajte uporabljati zdravilo Retacrit in se takoj posvetujte z zdravnikom ali poiščite medicinsko pomoč.
Starting dose of 50 IU/kg, 3 times per week, followed if necessary by a dosage increase with 25 IU/kg increments (3 times per week) until the desired goal is achieved (this should be done in steps of at least four weeks). 
Začetni odmerek je 50 i.e./trikrat tedensko, ki se ga po potrebi veča s koraki po 25 i.e./kg (trikrat tedensko), dokler se ne doseže zadana vrednost (koraki naj si sledijo s presledkom najmanj štirih tednov).
• The starting dose is either 150 IU per kilogram bodyweight three times a week or 450 IU per kilogram bodyweight once a week. 
• Začetni odmerek je bodisi 150 i.e. na kilogram telesne mase trikrat tedensko bodisi450 i.e. na kilogram telesne mase enkrat tedensko.
Where intravenous access is not readily available Retacrit may be administered subcutaneously. 
Kadar intravenski dostop ni takoj na razpolago, se lahko zdravilo Retacrit daje subkutano.
• Pinch a fold of skin between your thumb and index finger. 
• Primite kožno gubo med palec in kazalec in jo pridvignite.
Additional studies compared the 40 000 IU once-weekly regimen of epoetin alfa with biweekly doses ranging from 80 000 to 120 000 IU subcutaneously. 
V dodatnih študijah so primerjali odmerjanje 40.000 i.e. enkrat na teden z odmerki od 80.000 do 120.000 i.e. subkutano na dva tedna.
If the haemoglobin concentration has increased <1 g/dL (<0.62 mmol/L) and the reticulocyte count has increased <40 000 cells/µL above baseline, response is unlikely and treatment should be discontinued. 
Če pa se je koncentracija hemoglobina zvišala <1 g/dl (0,62 mmol/l) ali če se je število retikulocitov dvignilo <40.000 celic/µl nad osnovno vrednost, odziva verjetno ni in je treba zdravljenje prekiniti.
In cases where there is a medical need to shorten the lead time before surgery to less than three weeks, Retacrit 300 IU/kg should be administered subcutaneously daily for 10 consecutive days prior to surgery, on the day of surgery and for four days immediately thereafter. 
Če je treba zaradi zdravstvenih razlogov skrajšati čas pred kirurškim posegom na manj kot tri tedne, je treba dajati odmerek zdravila Retacrit 300 i.e./kg na dan subkutano, in sicer 10 dni zapored pred kirurškim posegom, na dan kirurškega posega in še štiri dni takoj po njem.
Due to intra-patient variability, occasional individual haemoglobin concentrations for a patient above and below the desired haemoglobin concentration range may be observed. 
Zaradi variabilnosti med bolniki lahko pri bolniku občasno ugotovite posamezne koncentracije hemoglobina nad ali pod zadanim koncentracijskim razponom hemoglobina.
The mean CL/F for the 150 IU/kg, 3-times-per-week and 40 000 IU, once-weekly regimens in the anaemic cancer subjects were 45.8 and 11.3 mL/h/kg, respectively. 
Povprečni CL/F pri režimih odmerjanja 150 i.e./kg trikrat na teden in 40.000 i.e. enkrat na teden pri anemičnih preskušancih z rakom je bil 45,8 ml/h/kg oziroma 11,3 ml/h/kg.
Caution should be exercised with escalation of erythropoiesis-stimulating agent (ESA) doses in patients with chronic renal failure. 
Pri višanju odmerkov zdravila za stimulacijo eritropoeze (ESA - erythropoiesis stimulating agent) pri bolnikih s kronično ledvično okvaro je potrebna previdnost.
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin concentration range may be observed. 
Zaradi razlik med posameznimi bolniki je pri bolnikih občasno mogoče opaziti individualne vrednosti hemoglobina, ki so nad ali pod želenim razponom koncentracije hemoglobina.
Retacrit is indicated for the treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL). 
≤ 10 g/dl) pri odraslih s primarnimi mielodisplastičnimi sindromi (MDS) z nizkim ali srednjim1 tveganjem, ki imajo nizke ravni eritropoetina v serumu (< 200 mU/ml).